Datapoint: FDA Approves First Interchangeable Humira Biosimilar

The FDA last week approved Boehringer Ingelheim’s Cyltezo as the first interchangeable biosimilar for AbbVie’s Humira. It is the second U.S.-approved interchangeable biosimilar overall, behind Viatris and Biocon’s Semglee. Cyltezo was approved for a number of inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriatic arthritis. For the treatment of rheumatoid arthritis, Humira holds preferred status under the pharmacy benefit for 11.6% of all covered lives, growing to 63.5% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 10/25/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 3

Datapoint: AstraZeneca, Merck Pull Lynparza in Ovarian Cancer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today